BUFFALO, NY--(Marketwire - February 19, 2008) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced results of a study demonstrating Protectan CBLB502’s ability to reduce the side effects of a chemotherapeutic drug, cisplatinum (Ciplatin, Platinol), broadly used for treatment of ovarian, endometrial, head and neck, lung, stomach and other types of cancer.
